Cipla USA Inc. received FDA approval Monday for Pomalidomide (ANDA219718), introducing an affordable oral alternative to the brand name drug for patients with multiple myeloma. This action is expected to broaden market accessibility by driving downstream competition against established Mylan and Amneal brands.